401 related articles for article (PubMed ID: 9384462)
1. Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity.
Lennard L; Welch JC; Lilleyman JS
Br J Clin Pharmacol; 1997 Nov; 44(5):455-61. PubMed ID: 9384462
[TBL] [Abstract][Full Text] [Related]
2. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
Lennard L; Cartwright CS; Wade R; Richards SM; Vora A
Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716
[TBL] [Abstract][Full Text] [Related]
3. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
[TBL] [Abstract][Full Text] [Related]
4. Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies.
Lennard L; Lewis IJ; Michelagnoli M; Lilleyman JS
Med Pediatr Oncol; 1997 Oct; 29(4):252-5. PubMed ID: 9251729
[TBL] [Abstract][Full Text] [Related]
5. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
[TBL] [Abstract][Full Text] [Related]
6. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE
J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024
[TBL] [Abstract][Full Text] [Related]
7. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
Nielsen SN; Toksvang LN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Appell ML; Hjalgrim LL; Schmiegelow K
Cancer Chemother Pharmacol; 2021 Aug; 88(2):271-279. PubMed ID: 33928426
[TBL] [Abstract][Full Text] [Related]
8. Role of TPMT and ITPA variants in mercaptopurine disposition.
Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
[TBL] [Abstract][Full Text] [Related]
9. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia.
McLeod HL; Relling MV; Liu Q; Pui CH; Evans WE
Blood; 1995 Apr; 85(7):1897-902. PubMed ID: 7703493
[TBL] [Abstract][Full Text] [Related]
10. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate.
Pettersson B; Almer S; Albertioni F; Söderhäll S; Peterson C
Ther Drug Monit; 2002 Jun; 24(3):351-8. PubMed ID: 12021625
[TBL] [Abstract][Full Text] [Related]
11. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism.
Bo J; Schrøder H; Kristinsson J; Madsen B; Szumlanski C; Weinshilboum R; Andersen JB; Schmiegelow K
Cancer; 1999 Sep; 86(6):1080-6. PubMed ID: 10491537
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of 6-Thioguanine and 6-Mercaptopurine Combination Maintenance Therapy of Childhood ALL: Hypothesis and Case Report.
Nielsen SN; Frandsen TL; Nersting J; Hjalgrim LL; Schmiegelow K
J Pediatr Hematol Oncol; 2015 Apr; 37(3):e206-9. PubMed ID: 25171455
[TBL] [Abstract][Full Text] [Related]
13. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia.
McLeod HL; Coulthard S; Thomas AE; Pritchard SC; King DJ; Richards SM; Eden OB; Hall AG; Gibson BE
Br J Haematol; 1999 Jun; 105(3):696-700. PubMed ID: 10354134
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine methyltransferase: a review and a clinical pilot study.
Keuzenkamp-Jansen CW; Leegwater PA; De Abreu RA; Lambooy MA; Bokkerink JP; Trijbels JM
J Chromatogr B Biomed Appl; 1996 Mar; 678(1):15-22. PubMed ID: 8861653
[TBL] [Abstract][Full Text] [Related]
15. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism.
Lennard L; Lilleyman JS
Ther Drug Monit; 1996 Aug; 18(4):328-34. PubMed ID: 8857546
[TBL] [Abstract][Full Text] [Related]
16. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.
Dervieux T; Médard Y; Verpillat P; Guigonis V; Duval M; Lescoeur B; Suciu S; Vilmer E; Jacqz-Aigrain E
Leukemia; 2001 Nov; 15(11):1706-12. PubMed ID: 11681411
[TBL] [Abstract][Full Text] [Related]
17. Thiopurine S-methyltransferase phenotype-genotype correlation in children with acute lymphoblastic leukemia.
Chrzanowska M; Kuehn M; Januszkiewicz-Lewandowska D; Kurzawski M; Droździk M
Acta Pol Pharm; 2012; 69(3):405-10. PubMed ID: 22594254
[TBL] [Abstract][Full Text] [Related]
18. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.
Lennard L; Lilleyman JS; Van Loon J; Weinshilboum RM
Lancet; 1990 Jul; 336(8709):225-9. PubMed ID: 1973780
[TBL] [Abstract][Full Text] [Related]
19.
Dreisig K; Brünner ED; Marquart HV; Helt LR; Nersting J; Frandsen TL; Jonsson OG; Taskinen M; Vaitkeviciene G; Lund B; Abrahamsson J; Lepik K; Schmiegelow K
Pediatr Hematol Oncol; 2021 Apr; 38(3):227-238. PubMed ID: 33205673
[TBL] [Abstract][Full Text] [Related]
20. [Significance of TPMT activity and TGNs level detection for individualizing 6-mercaptopurine chemotherapy].
Gu LJ; Ye QD; Liang AB; Zhao JC; Xue HL; Tang YN; Chen J; Ye YC
Zhonghua Xue Ye Xue Za Zhi; 2003 Jan; 24(1):18-21. PubMed ID: 12679004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
